|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2006-8-28
|
|
pubmed:abstractText |
Chemokines such as CCL2/monocyte chemotactic protein 1 (MCP-1) play a key role in leukocyte migration and are potential targets in the treatment of chronic inflammatory disorders. The objective of this study was to evaluate the effects of human anti-CCL2/MCP-1 monoclonal antibody (ABN912) treatment in patients with rheumatoid arthritis (RA).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0004-3591
|
|
pubmed:author |
pubmed-author:BaetenDominiqueD,
pubmed-author:BreedveldFerdinand CFC,
pubmed-author:BresnihanBarryB,
pubmed-author:DinantHuib JHJ,
pubmed-author:GerlagDanielle MDM,
pubmed-author:GramHermannH,
pubmed-author:HaringmanJasper JJJ,
pubmed-author:LegayFrancoisF,
pubmed-author:LoetscherPiusP,
pubmed-author:ParrotPP,
pubmed-author:SchmouderRobertR,
pubmed-author:SmeetsTom J MTJ,
pubmed-author:WoodworthThasiaT,
pubmed-author:van den BoschFilipF
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
54
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2387-92
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16869001-Adult,
pubmed-meshheading:16869001-Aged,
pubmed-meshheading:16869001-Antibodies, Monoclonal,
pubmed-meshheading:16869001-Antirheumatic Agents,
pubmed-meshheading:16869001-Arthritis, Rheumatoid,
pubmed-meshheading:16869001-Biological Markers,
pubmed-meshheading:16869001-Biopsy,
pubmed-meshheading:16869001-Chemokine CCL2,
pubmed-meshheading:16869001-Dose-Response Relationship, Drug,
pubmed-meshheading:16869001-Female,
pubmed-meshheading:16869001-Humans,
pubmed-meshheading:16869001-Image Processing, Computer-Assisted,
pubmed-meshheading:16869001-Immunohistochemistry,
pubmed-meshheading:16869001-Immunologic Factors,
pubmed-meshheading:16869001-Male,
pubmed-meshheading:16869001-Middle Aged,
pubmed-meshheading:16869001-Synovial Membrane,
pubmed-meshheading:16869001-Treatment Outcome
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis.
|
|
pubmed:affiliation |
Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Multicenter Study
|
